Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00050401 | Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia Requiring Mechanical Ventilatory Support | PHASE3 | COMPLETED | 500 | — | — | Jul 1, 2002 | Sep 1, 2004 | Sep 1, 2017 | 10 | United States |
| Name | Type | Description |
|---|---|---|
| MERREM I.V. 2g as a 3 hour infusion every 8 hours | DRUG | - |
| vancomycin I.V. 1 g every 12 hours | DRUG | - |
| tobramycin I.V. 5 mg/kg every 24 hours | DRUG | - |
| MERREM I.V. 1g as a 30 minute infusion every 8 hours | DRUG | - |
| MERREM I.V. 500 mg as a 3 hour infusion every 8 hours | DRUG | - |
Inclusion Criteria: * Onset or exacerbation of pneumonia at least 72 hours after admission to an acute care facility or onset of pneumonia in a nursing home or rehabilitation facility with subsequent transfer to an acute care facility * Diagnosis of hospital-acquired pneumonia requiring mechanical ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE3 | Tozorakimab |
| GSK plc Sponsored ADR | GSK | 3 | PHASE1 | Pn-MAPS30plus, PCV20 |
| Pfizer Inc. | PFE | 4 | — | Receipt of PCV20 |
| Sanofi SA Sponsored ADR | SNY | 1 | — | Undisclosed |
| Gilead Sciences, Inc. | GILD | 1 | — | Undisclosed |
| Grace Therapeutics, Inc. | GRCE | 1 | NA | Undisclosed |
| Co-Diagnostics, Inc. | CODX | 1 | — | Undisclosed |